首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis
【2h】

Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis

机译:浸润性导管癌的拓扑学:空间蛋白表达成像和定量蛋白质组特征分析的结合

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Due to enormous advances in quantitative proteomics and in immunohistochemistry (pathology), the two research areas have now reached the state to be successfully interwoven in order to tackle challenges in toponostics and to open tumor-targeted systems pathology approaches. In this study the differential expressions of candidate proteins nucleophosmin, nucleoside diphosphate kinase A/B (NDKA/B), osteoinducive factor (mimecan), and pyru-vate kinase M2 from a quantitative proteome signature for invasive ductal breast cancer were determined by immunohistochemistry on 53 tissue slices from formalin-fixed and paraffin-embedded tumor and control tissue samples from ten patients and fourteen controls. In addition, 87 images from the Human Protein Atlas representing seven tumor and nine normal breast tissue samples were investigated by computer-assisted semi-quantitative density measurements on nucleophosmin, nucleoside diphosphate kinase A/B (NDKA/B), osteoinducive factor (mimecan), pyruvate kinase M2, glyceraldehyde-3-phosphate dehydro-genase (GAP-DH), and mimecan (osteoinductive factor). Both IHC data sets match well to each other and support the quantitative proteome analysis data. Determining spatial distribution of signature protein expressions by protein imaging on morphologically intact tissue samples at the sub-cellular level and, hence, keeping all topological information, presents an added value to quantitative proteome data. Such comprehensive data sets are needed for both, pathway analyses and for “next generation clinical diagnostics” approaches.
机译:由于定量蛋白质组学和免疫组织化学(病理学)的巨大进步,这两个研究领域现已进入成功交织的状态,以应对纵断层学方面的挑战并开放以肿瘤为靶标的系统病理学方法。在这项研究中,通过免疫组化技术通过定量蛋白质组学测定了候选蛋白质核磷酸蛋白,核苷二磷酸激酶A / B(NDKA / B),骨诱导因子(mimecan)和丙酮酸激酶M2的差异表达。来自十名患者和十四名对照的福尔马林固定和石蜡包埋的肿瘤以及对照组织样品的53个组织切片。此外,还通过计算机辅助半定量密度测量法对核蛋白,核苷二磷酸激酶A / B(NDKA / B),骨诱导因子(mimecan)进行了研究,从人类蛋白质图谱中获得了代表七个肿瘤和九个正常乳腺组织样本的87张图像。 ,丙酮酸激酶M2、3-磷酸甘油醛脱氢酶(GAP-DH)和mimecan(成骨诱导因子)。 IHC的两个数据集相互匹配,并支持蛋白质组学定量分析数据。通过在亚细胞水平上对形态完整的组织样品进行蛋白质成像来确定标志性蛋白质表达的空间分布,并因此保留所有拓扑信息,为定量蛋白质组数据提供了附加价值。路径分析和“下一代临床诊断”方法都需要此类综合数据集。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号